37 - Eat the Apple: Genesis of Antimicrobial Resistance

Thursday, September 30, 2021

3:45 PM - 5:00 PM EDT

Moderator(s)

Michael Glickman, MD, FIDSA, FAAM

Member, Attending Physician
Memorial Sloan Kettering
New York, NY, United States

Fimbrion Therapeutics (Individual(s) Involved: Self): Consultant; Pathogen Response Lab (Individual(s) Involved: Self): Board Member; Vedanta Biosciences (Individual(s) Involved: Self): Board Member, Shareholder
Anne-Catrin Uhlemann, MD, PhD

Associate Professor
Medicine/Infectious Diseases
Columbia University Irving Medical Center
New York, NY, United States

Merck (Individual(s) Involved: Self): Grant/Research Support

Speaker(s)

Rahul Kohli, MD, PhD

Associate Professor
University of Pennsylvania
Philadelphia, PA, United States

Cambridge Epigenetix (Individual(s) Involved: Self): Board Member; LifeEdit Inc. (Individual(s) Involved: Self): Board Member
Brandon Ogbunu, PhD

Assistant Professor
Yale University

I do not have any relevant financial / non-financial relationships with any proprietary interests.
Allison Lopatkin, PhD

Assistant Professor
Barnard College, Columbia University, United States

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Participants should be aware of the following financial/non-financial relationships:

Michael S. Glickman, MD, FIDSA, FAAM: Fimbrion Therapeutics (Individual(s) Involved: Self): Consultant; Pathogen Response Lab (Individual(s) Involved: Self): Board Member; Vedanta Biosciences (Individual(s) Involved: Self): Board Member, Shareholder

Anne-Catrin Uhlemann, MD, PhD: Merck (Individual(s) Involved: Self): Grant/Research Support

Rahul M. Kohli, MD, PhD: Cambridge Epigenetix (Individual(s) Involved: Self): Board Member; LifeEdit Inc. (Individual(s) Involved: Self): Board Member

Brandon Ogbunu, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Allison J. Lopatkin, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit

No CPE credits

Learning Objectives:

At the conclusion of this session, participants will be able to:

explain the role of bacterial DNA repair pathways in generating resistance
discuss the role of metabolic environments in promoting resistance
list new ways of intervening against the development of antimicrobial resistance

Presentations:

Disarming the Bacterial DNA Damage Response to Combat Antibiotic Resistance
Speaker: Rahul M. Kohli, MD, PhD – University of Pennsylvania
Evolutionary Tradeoffs in Antimicrobial Resistance
Speaker: Brandon Ogbunu, PhD – Yale University
Metabolic Determinants of Antibiotic Resistance in Bacteria
Speaker: Allison J. Lopatkin, PhD – Barnard College, Columbia University